Lonsurf Approval History
- FDA approved: Yes (First approved September 22nd, 2015)
- Brand name: Lonsurf
- Generic name: tipiracil hydrochloride and trifluridine
- Dosage form: Capsules
- Company: Taiho Oncology, Inc.
- Treatment for: Colorectal Cancer
Lonsurf (tipiracil and trifluridine) is a thymidine phosphorylase inhibitor and nucleoside metabolic inhibitor combination indicated for the treatment of patients with metastatic colorectal cancer who are no longer responding to other therapies.
Development History and FDA Approval Process for Lonsurf
|Sep 22, 2015||FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer|
|Feb 23, 2015||Taiho Oncology, Inc. Announces TAS-102 NDA for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.